Payment overview · 2025
General Payments
$961.80
53 reported records · 18 companies
Healthcare provider profile · identity verified
Andrew J Blank, DO
Allopathic & Osteopathic Physicians|General Practice · BURLINGTON, NJ · NPI 1184720542
Verified facts
What the public records show
CMS Open Payments records show Andrew J Blank, DO received $961.80 in general payments during 2025 across 53 reported records.
AstraZeneca Pharmaceuticals LP accounted for 14.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Ozempic, Rexulti, Rybelsus, Shingrix.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 640 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 640 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $141.20 | 14.7% | 8 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $117.27 | 12.2% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $107.34 | 11.2% | 6 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $98.06 | 10.2% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $86.64 | 9.0% | 5 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $61.44 | 6.4% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $48.19 | 5.0% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $48.18 | 5.0% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $37.19 | 3.9% | 2 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $33.00 | 3.4% | 2 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $32.58 | 3.4% | 2 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $30.88 | 3.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $27.84 | 2.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.48 | 2.2% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $19.11 | 2.0% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.80 | 1.9% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $16.47 | 1.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.13 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $961.80 | 53 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $165.46 | 9 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $110.41 | 6 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $98.06 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $86.64 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $86.64 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $69.84 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $69.84 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $61.44 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $37.19 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $37.19 | 2 | 2025 |
Source payment records
|
|||||
| Belbuca Normalized: belbuca |
Drug | Collegium Pharmaceutical, Inc. | $33.00 | 2 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $32.58 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $32.22 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $31.35 | 2 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $30.88 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $30.79 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $27.84 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $21.48 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $20.49 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $19.11 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $18.80 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.83 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $16.47 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.13 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 640 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 46 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 123 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
640 | 107 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
28 | 26 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
123 | 88 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
108 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
72 | 15 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
46 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
140 | 139 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
640 | 107 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1344 | 333 |
| Amlodipine Besylate | Amlodipine Besylate | 958 | 243 |
| Eliquis | Apixaban | 640 | 107 |
| Levothyroxine Sodium | Levothyroxine Sodium | 638 | 160 |
| Losartan Potassium | Losartan Potassium | 546 | 145 |
| Pantoprazole Sodium | Pantoprazole Sodium | 484 | 156 |
| Metoprolol Succinate | Metoprolol Succinate | 458 | 123 |
| Gabapentin | Gabapentin | 433 | 132 |
| Furosemide | Furosemide | 432 | 128 |
| Metformin Hcl | Metformin Hcl | 424 | 110 |
| Alprazolam | Alprazolam | 376 | 84 |
| Lisinopril | Lisinopril | 354 | 92 |
| Sertraline Hcl | Sertraline Hcl | 346 | 65 |
| Tamsulosin Hcl | Tamsulosin Hcl | 342 | 98 |
| Trazodone Hcl | Trazodone Hcl | 325 | 76 |
| Donepezil Hcl | Donepezil Hcl | 318 | 60 |
| Omeprazole | Omeprazole | 315 | 97 |
| Escitalopram Oxalate | Escitalopram Oxalate | 289 | 53 |
| Famotidine | Famotidine | 287 | 92 |
| Carvedilol | Carvedilol | 272 | 88 |
| Clopidogrel | Clopidogrel Bisulfate | 265 | 61 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 244 | 72 |
| Hydrochlorothiazide | Hydrochlorothiazide | 241 | 71 |
| Buspirone Hcl | Buspirone Hcl | 235 | 54 |
| Metoprolol Tartrate | Metoprolol Tartrate | 222 | 76 |
| Mresvia | Rsv Vaccine, Pref, Mrna/Pf | 220 | 220 |
| Hydralazine Hcl | Hydralazine Hcl | 219 | 60 |
| Potassium Chloride | Potassium Chloride | 219 | 72 |
| Simvastatin | Simvastatin | 209 | 54 |
| Allopurinol | Allopurinol | 207 | 61 |
| Montelukast Sodium | Montelukast Sodium | 197 | 47 |
| Mirtazapine | Mirtazapine | 194 | 47 |
| Divalproex Sodium | Divalproex Sodium | 176 | 25 |
| Memantine Hcl | Memantine Hcl | 168 | 33 |
| Tramadol Hcl | Tramadol Hcl | 156 | 51 |
| Pravastatin Sodium | Pravastatin Sodium | 155 | 44 |
| Glimepiride | Glimepiride | 153 | 51 |
| Baclofen | Baclofen | 151 | 47 |
| Ondansetron Hcl | Ondansetron Hcl | 149 | 57 |
| Quetiapine Fumarate | Quetiapine Fumarate | 147 | 29 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 140 | 139 |
| Duloxetine Hcl | Duloxetine Hcl | 137 | 37 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 137 | 38 |
| Levetiracetam | Levetiracetam | 131 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 129 | 48 |
| Finasteride | Finasteride | 129 | 34 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 123 | 88 |
| Repaglinide | Repaglinide | 120 | 38 |
| Nifedipine Er | Nifedipine | 119 | 28 |
| Januvia | Sitagliptin Phosphate | 118 | 20 |
| Ezetimibe | Ezetimibe | 115 | 35 |
| Jardiance | Empagliflozin | 108 | 18 |
| Bupropion Xl | Bupropion Hcl | 106 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 99 | 26 |
| Meloxicam | Meloxicam | 95 | 30 |
| Ramipril | Ramipril | 95 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 88 | 47 |
| Olanzapine | Olanzapine | 85 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 85 | 17 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 82 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 82 | 30 |
| Xarelto | Rivaroxaban | 78 | 18 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 76 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 76 | 15 |
| Lorazepam | Lorazepam | 76 | 21 |
| Spironolactone | Spironolactone | 75 | 36 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 74 | 15 |
| Midodrine Hcl | Midodrine Hcl | 72 | 19 |
| Trulicity | Dulaglutide | 72 | 15 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 71 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 70 | 16 |
| Meclizine Hcl | Meclizine Hcl | 67 | 25 |
| Ibuprofen | Ibuprofen | 66 | 28 |
| Sucralfate | Sucralfate | 64 | 14 |
| Clonazepam | Clonazepam | 63 | 12 |
| Prednisone | Prednisone | 63 | 28 |
| Metformin Hcl Er | Metformin Hcl | 62 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 61 | 23 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 60 | 16 |
| Amiodarone Hcl | Amiodarone Hcl | 59 | 20 |
| Glipizide | Glipizide | 59 | 14 |
| Enalapril Maleate | Enalapril Maleate | 58 | 12 |
| Bumetanide | Bumetanide | 56 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 56 | 24 |
| Securesafe Pen Needle | Pen Needle, Diabetic, Safety | 56 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 55 | 12 |
| Warfarin Sodium | Warfarin Sodium | 54 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 54 | 15 |
| Acetic Acid | Acetic Acid | 51 | 21 |
| Atenolol | Atenolol | 51 | 17 |
| Dicyclomine Hcl | Dicyclomine Hcl | 50 | 13 |
| Memantine Hcl Er | Memantine Hcl | 50 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 49 | 16 |
| Torsemide | Torsemide | 49 | 14 |
| Latanoprost | Latanoprost | 48 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 48 | 18 |
| Alendronate Sodium | Alendronate Sodium | 46 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 46 | 12 |
| Ozempic | Semaglutide | 46 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 45 | 12 |
| Risperidone | Risperidone | 43 | 14 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 42 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 42 | 12 |
| Linzess | Linaclotide | 42 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 41 | 21 |
| Alogliptin | Alogliptin Benzoate | 41 | 11 |
| Cephalexin | Cephalexin | 41 | 27 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 41 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 41 | 23 |
| Nystatin | Nystatin | 41 | 26 |
| Clonidine Hcl | Clonidine Hcl | 40 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 40 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 40 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 40 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 38 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 38 | 38 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 38 | 13 |
| Mupirocin | Mupirocin | 38 | 26 |
| Pregabalin | Pregabalin | 38 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 38 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 38 | 11 |
| Divalproex Sodium Er | Divalproex Sodium | 37 | 11 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 37 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 37 | 11 |
| Ammonium Lactate | Ammonium Lactate | 36 | 19 |
| Azithromycin | Azithromycin | 36 | 27 |
| Xifaxan | Rifaximin | 36 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 35 | 11 |
| Digoxin | Digoxin | 35 | suppressed |
| Movantik | Naloxegol Oxalate | 34 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Levofloxacin | Levofloxacin | 33 | 22 |
| Propranolol Hcl | Propranolol Hcl | 33 | suppressed |
| Lactulose | Lactulose | 32 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 32 | 12 |
| Budesonide | Budesonide | 31 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | suppressed |
| Lovastatin | Lovastatin | 31 | suppressed |
| Methylprednisolone | Methylprednisolone | 31 | 23 |
| Loperamide | Loperamide Hcl | 30 | 22 |
| Valsartan | Valsartan | 30 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 30 | suppressed |
| Amoxicillin | Amoxicillin | 29 | 20 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 29 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 19 |
| Nateglinide | Nateglinide | 29 | suppressed |
| Nystop | Nystatin | 29 | 15 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 28 | 26 |
| Celecoxib | Celecoxib | 28 | 14 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 28 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 27 | suppressed |
| Entresto | Sacubitril/Valsartan | 27 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 26 | suppressed |
| Lamotrigine | Lamotrigine | 26 | suppressed |
| Roflumilast | Roflumilast | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 26 | 14 |
| Terazosin Hcl | Terazosin Hcl | 26 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Lansoprazole | Lansoprazole | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | suppressed |
| Creon | Lipase/Protease/Amylase | 24 | suppressed |
| Folic Acid | Folic Acid | 24 | suppressed |
| Ketoconazole | Ketoconazole | 24 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 23 | suppressed |
| Novolog Flexpen | Insulin Aspart | 23 | 13 |
| Silver Sulfadiazine | Silver Sulfadiazine | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | suppressed |
| Aripiprazole | Aripiprazole | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Glatopa | Glatiramer Acetate | 22 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 22 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 22 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 22 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 22 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 20 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Acetazolamide | Acetazolamide | 19 | suppressed |
| Calcium Acetate | Calcium Acetate | 19 | suppressed |
| Cilostazol | Cilostazol | 19 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 19 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 19 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 19 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 18 | 12 |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 18 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 18 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 18 | suppressed |
| Rybelsus | Semaglutide | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Calcitriol | Calcitriol | 17 | suppressed |
| Clotrimazole | Clotrimazole | 17 | suppressed |
| Dutasteride | Dutasteride | 17 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | 11 |
| Incruse Ellipta | Umeclidinium Bromide | 17 | suppressed |
| Ssd | Silver Sulfadiazine | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 12 |
| Humalog Kwikpen U-200 | Insulin Lispro | 16 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 16 | suppressed |
| Methotrexate | Methotrexate Sodium | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | 16 |
| Telmisartan | Telmisartan | 16 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Cyclosporine | Cyclosporine | 15 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 15 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 15 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 15 | suppressed |
| Lubiprostone | Lubiprostone | 15 | suppressed |
| Metolazone | Metolazone | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 14 |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | 11 |
| Nyamyc | Nystatin | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Velphoro | Sucroferric Oxyhydroxide | 14 | suppressed |
| Acetylcysteine | Acetylcysteine | 13 | suppressed |
| Amantadine | Amantadine Hcl | 13 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Butalbital-Acetaminophen | Butalbital/Acetaminophen | 13 | suppressed |
| Cefadroxil | Cefadroxil | 13 | 11 |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 13 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 12 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Desloratadine | Desloratadine | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 11 | suppressed |
| Carbamazepine Er | Carbamazepine | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide/Timolol/Pf | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $961.80 · 53 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BEYFORTUS, BREZTRI, Belbuca, CAPLYTA, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FANAPT, FARXIGA, INSPIRE, KRYSTEXXA, Kerendia, MOUNJARO, NEFFY, NURTEC ODT, Ozempic, REXULTI, Rybelsus, SHINGRIX, Wegovy, ZAVZPRET, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error